Medannex is an award-winning Scottish biopharmaceutical company committed to unlocking the therapeutic potential of targeting annexin-A1.

Our goal is to create a first-in-class therapy to improve the lives of people impacted by cancers and autoimmune diseases.

Following a recent Series B fundraise, and supported by both the Scottish Investment Bank and Innovate UK, Medannex is collaborating with world-leading clinical experts to explore the huge therapeutic and commercial potential of our patent-protected immunomodulatory technology.

Medannex has been shortlisted as a finalist for both ‘Investment of the Year’ and ‘Outstanding Skills Development’ at Scotland’s Life Sciences Annual Awards 2020.


Medannex is a proud signatory of the Scottish Business Pledge, showing our commitment to building sustainable growth whilst maintaining fairness, equality, opportunity and innovation.


Meet the Team

Latest News

“Medannex has identified a novel and promising target for immunotherapy, and I am delighted to offer guidance as the company prepares for its First-in-Human study.”

Dr Stefan Symeonides,
head of Phase I Trials at the CRUK Edinburgh Centre

Collaborations & Affiliations

Medannex is proud to collaborate with leading academic researchers, play an active role within several industry associations and provide extensive skills development opportunities.

Medannex continues to operate during the COVID-19 pandemic, although many of our key collaborators have temporarily ceased activities and those that are still operational have limited capacity. We are taking steps wherever possible to minimise the inevitable disruption to our development programme.

We fully support the necessary actions taken by all of our partners to protect employees and their families during this very difficult period.

We all look forward to returning to full-scale development as soon as possible. Stay safe.